View Older Stories View More Recent Stories
-
Shares of vaccine makers drop after FDA memo flags reports of child deaths
-
UK and US poised to agree zero-tariffs deal on pharmaceuticals - The Times
-
This pharma stock is BofA's Top Pick going into 2026
-
AstraZeneca wins FDA approval for IMFINZI as first perioperative immunotherapy for early gastric cancers
-
Bernstein on IRA pricing: $245 really is the floor
-
AstraZeneca's Imfinzi gets FDA approval for early gastric cancer treatment
-
AstraZeneca (AZN) PT Raised to $108.50 at BofA Securities
-
AstraZeneca announces $2 billion Maryland manufacturing expansion
-
AstraZeneca (AZN) PT Raised to $87 at Leerink Partners
-
baxdrostat shows significant blood pressure reduction in resistant hypertension trial
-
AstraZeneca's FASENRA shows positive results in rare blood disorder trial
-
Axsome Therapeutics acquires epilepsy drug candidate from AstraZeneca
-
AstraZeneca (AZN) Tops Q3 EPS by 122c; offers guidance
-
AstraZeneca earnings preview Q3: stronger print expected, focus on US prices, pipeline
-
Trump announcement on weight loss drugs scheduled for 11 A.M. Thursday; price to drop under $150/mo - CBS
-
AstraZeneca (AZN) call put ratio 2.1 calls to 1 put into quarter results
-
AstraZeneca's gefurulimab meets primary endpoint in myasthenia gravis trial
-
AstraZeneca's Alexion to present gefurulimab trial data at neurology meetings
-
Koselugo wins EU approval for adult neurofibromatosis type 1 tumors
-
Jefferies Upgrades AstraZeneca (AZN:LN) (AZN) to Buy
-
Tezspire wins EU approval for chronic rhinosinusitis with nasal polyps
-
AstraZeneca's Tezspire gets FDA approval for nasal polyp condition
-
UK closes in on drug pricing deal with White House - FT
-
AstraZeneca's IMFINZI shows 32% risk reduction in bladder cancer trial
-
AstraZeneca's IMFINZI shows survival benefit in early gastric cancer trial
-
AstraZeneca cut to Sell by Deutsche Bank on pipeline doubts, patent risk
-
Deutsche Bank Downgrades AstraZeneca (AZN:LN) (AZN) to Sell
-
AstraZeneca completes $445 million Texas facility expansion
-
AstraZeneca opens expanded Texas manufacturing facility
-
AstraZeneca presents initial data from four pivotal cancer trials at ESMO
-
AstraZeneca agrees to lower US drug prices, delay tariffs
-
Trump: AstraZeneca is committing to discounts
-
AstraZeneca (AZN) to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs
-
Astrazeneca (AZN) Strikes Deal With White House On Drug Prices - MSNBC
-
AstraZeneca to invest $4.5 billion in Virginia manufacturing facility
-
Turbine partners with AstraZeneca on AI-driven drug discovery platform
-
AstraZeneca's baxdrostat meets primary endpoint in resistant hypertension trial
-
AstraZeneca's baxdrostat meets primary endpoint in phase III trial
-
Acting CDC head Jim O’neill: I call on vaccine manufacturers to develop safe monovalent vaccines to replace the combined MMR - X post
-
DATROWAY shows survival benefit in triple-negative breast cancer trial
-
DATROWAY shows survival benefit for triple negative breast cancer
-
AstraZeneca (AZN) India - receives permission to import Enhertu
-
AstraZeneca (AZN) options active option volume of 36K contracts
-
Trump on deal with Pfizer: we're going to be paying the lowest price, other drugmakers will commit in coming weeks
-
Trump says we’ll be reducing prices (of drugs) by a 100% and in some cases more
-
ENHERTU shows improvement over T-DM1 in early breast cancer trial
-
Britain would face 100% tariffs on U.S. pharmaceuticals under latest Trump's plan - Reuters
-
EU will still have 15% pharma tariff, not 100% - Bloomberg
-
AstraZeneca launches direct-to-consumer platform for US patients
-
AstraZeneca's Enhertu gets FDA priority review for breast cancer
